Results 81 to 90 of about 3,073 (170)

Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]

Mediterr J Hematol Infect Dis
Marzi F, Alessandri M, De Crescenzo V, Del Vecchio S, Radi S, Manini M.   +5 more
europepmc   +1 more source

Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection

Infection and Drug Resistance
Ignacy Tarski,1 Jakub Śmiechowicz,2 Wiesława Duszyńska2 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland; 2Department and Clinic of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw ...
Tarski I, Śmiechowicz J, Duszyńska W
doaj  

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing <i>Klebsiella pneumoniae</i> in the hollow fiber infection model. [PDF]

Antimicrob Agents Chemother
Singh N, Jogan CML, Zang Y, Shan X, Lang Y, Karunanidhi A, Watkins JV, Curry BN, Tamma PD, Nozick SH, Ozer EA, Hauser AR, Bulitta JB, Bulman ZP.   +13 more
europepmc   +1 more source

<i>In vitro</i> activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023. [PDF]

JAC Antimicrob Resist
Karlowsky JA, Estabrook M, Suzuki E, Shimizu A, Okade H.   +4 more
europepmc   +1 more source

Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]

Microbiol Resour Announc
Ozer EA, Nozick SH, Singh N, Watkins JV, Hauser AR, Bulman ZP.   +5 more
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. [PDF]

Antimicrob Agents Chemother
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD.   +9 more
europepmc   +1 more source

Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients. [PDF]

J Antimicrob Chemother
Cojutti PG, Toschi A, Pasquini Z, Paolini S, Maffini E, Bonifazi F, Zinzani PL, Giannella M, Viale P, Pea F.   +9 more
europepmc   +1 more source

Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study. [PDF]

J Antimicrob Chemother
Frallonardo L, Guido G, De Gennaro N, De Iaco G, Signorile F, Cibelli M, De Luca A, Ritacco AI, Stolfa S, Di Gennaro F, Saracino A.   +10 more
europepmc   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source